The use of AI neural networks can help advance the development of gene therapy drugs

  

Gene Therapy in Ophthalmology: New Opportunities for Vision Restoration.

The use of AI neural networks can help advance the development of gene therapy drugs

Keynote Speaker: Han Lanqing.

Director of the AI Innovation Center at the Tsinghua Pearl River Research Institute.

Founder of Cyagen and RDDC Development Director.

Executive Secretary General of Guangzhou Rare Disease Gene Therapy Alliance.

  

In the field of gene therapy, although AAV is a highly effective delivery vector, there are still limitations in treating some inherited eye diseases. How to overcome these limitations?

 

Mr. Han Lanqing, Director of the AI Innovation Center of Tsinghua Pearl River Research Institute and Executive Secretary-General of the Guangzhou Rare Disease Gene Therapy Alliance, stated that from the perspective of AI synthetic biology and directed evolution, better vectors may be discovered to assist in the development of gene therapy drugs for rare diseases. Click on the video to follow Mr. Han's introduction and learn more about this topic.

 

Entering the RDDC official website (https://rddc.tsinghua-gd.org/), users can use AI tools.

 

Gene Therapy for Ophthalmology: New Opportunities for Restoring Sight

 

Inherited eye diseases are caused by genetic defects and often manifest as hereditary diseases. There are about 5 million blind people in China, of which inherited eye diseases account for about one-third of childhood blindness and visual impairment, and 80% of blindness and severe visual impairment; patients with monogenic inherited eye diseases account for about 4% of the total population. Compared with traditional medical methods, gene therapy as an innovative development field is thriving both domestically and abroad. Similarly, it has also made significant breakthroughs in the diagnosis and treatment of inherited eye diseases. Governments, enterprises, and research institutions are all actively promoting the industrialization of gene therapy drugs for ophthalmology.

 

For this purpose, the Tsinghua Pearl River Research Institute has partnered with Sino Biological to develop the Rare Diseases Data Center (RDDC) and a series of AI tools, such as the AI Pathogenicity Prediction Tool and the AI Splice Prediction Tool, to assist in the diagnosis and research of rare diseases, and support the development of gene therapy drugs.

 

Based on this, the Guangzhou Rare Disease Gene Therapy Alliance has invited experts such as Professor Jin Zibing from Beijing Tongren Hospital of Capital Medical University, Professor Liu Chunqiao from Zhongshan Ophthalmic Center of Sun Yat-sen University, Professor Fan Guoping from Alcon BioPharmaceuticals, Dr. Zhang Wei from Jiajian Medical, Director Han Lanqing from Tsinghua Pearl River Research Institute's AI Innovation Center, and Dr. Ren Sheng from Sino Biological's Gene Therapy Department to participate in a salon event with the theme "Gene Therapy for Ophthalmology: New Opportunities for Restoring Sight" to jointly discuss the current situation and future prospects of gene therapy for inherited eye diseases.